Literature DB >> 7927807

Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.

N Orr1, R Arnon, G Rubin, D Cohen, H Bercovier, G H Lowell.   

Abstract

Addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a lipopolysaccharide vaccines improved their immunogenicities. Enhancement of anti-O-Shigella immunoglobulin A levels was most evident in lung lavages following oral immunization and in lung and intestinal fluids when suboptimal doses were used with either immunization route.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7927807      PMCID： PMC303249          DOI： 10.1128/iai.62.11.5198-5200.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  14 in total

1.  Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization.

Authors:  M Vajdy; N Y Lycke
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

2.  Biliary immune response to orally presented food antigen, ovomucoid, and its potentiation by cholera toxin B subunit.

Authors:  Y Sugita-Konishi; S Kumagai
Journal:  Scand J Immunol       Date:  1992-05       Impact factor: 3.487

3.  Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response.

Authors:  K S Chen; W Strober
Journal:  Eur J Immunol       Date:  1990-02       Impact factor: 5.532

4.  Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine.

Authors:  S I Tamura; Y Samegai; H Kurata; K Kikuta; T Nagamine; C Aizawa; T Kurata
Journal:  Vaccine       Date:  1989-06       Impact factor: 3.641

5.  Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors:  D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

6.  Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.

Authors:  H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

7.  Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.

Authors:  N Lycke; J Holmgren
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

8.  Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.

Authors:  Y Hirabayashi; H Kurata; H Funato; T Nagamine; C Aizawa; S Tamura; K Shimada; T Kurata
Journal:  Vaccine       Date:  1990-06       Impact factor: 3.641

9.  Immune response related to the molecular structure of a peptide from the cholera toxin B subunit.

Authors:  H Halimi; P Rivaille
Journal:  Vaccine       Date:  1993-09       Impact factor: 3.641

10.  Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.

Authors:  R E Black; M M Levine; M L Clements; G Losonsky; D Herrington; S Berman; S B Formal
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226
View more
  4 in total

1.  Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.

Authors:  C P Mallett; T L Hale; R W Kaminski; T Larsen; N Orr; D Cohen; G H Lowell
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

2.  Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.

Authors:  G H Lowell; R W Kaminski; S Grate; R E Hunt; C Charney; S Zimmer; C Colleton
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

3.  Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.

Authors:  Reinaldo Acevedo; Adriana Callicó; Yisabel Aranguren; Caridad Zayas; Yolanda Valdés; Oliver Pérez; Luis García; Valerie A Ferro; José Luis Pérez
Journal:  BMC Immunol       Date:  2013-02-25       Impact factor: 3.615

Review 4.  From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology.

Authors:  Diana Boraschi; Paola Italiani
Journal:  Vaccines (Basel)       Date:  2015-11-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.